StemCell Therapy

SEATTLE--(BUSINESS WIRE)--Today at AWS re:Invent, Amazon Web Services, Inc. (AWS), an Amazon.com company (NASDAQ: AMZN) announced Amazon HealthLake, a HIPAA-eligible service for healthcare and life sciences organizations. Amazon HealthLake aggregates an organizations complete data across various silos and disparate formats into a centralized AWS data lake and automatically normalizes this information using machine learning. The service identifies each piece of clinical information, tags, and indexes events in a timeline view with standardized labels so it can be easily searched, and structures all of the data into the Fast Healthcare Interoperability Resources (FHIR) industry standard format for a complete view of the health of individual patients and entire populations. As a result, Amazon HealthLake makes it easier for customers to query, perform analytics, and run machine learning to derive meaningful value from the newly normalized data. Organizations such as healthcare systems, pharmaceutical companies, clinical researchers, health insurers, and more can use Amazon HealthLake to help spot trends and anomalies in health data so they can make much more precise predictions about the progression of disease, the efficacy of clinical trials, the accuracy of insurance premiums, and many other applications. To learn more about Amazon HealthLake, visit: https://aws.amazon.com/healthlake.

As machine learning becomes more mainstream, companies across every vertical business are trying to apply it to their data to deliver meaningful business value. Healthcare is applying machine learning to improve operations and patient care, with AWS customers like 3M, Anthem, AstraZeneca, Bristol Myers Squibb, Cerner, the Fred Hutchinson Cancer Research Center, GE Healthcare, Infor, Pfizer, and Philips embracing the cloud and machine learning to get more value out of their vast data troves. From family history and clinical observations to diagnoses and medications, healthcare organizations are creating huge volumes of patient information every day with the goal of getting a full view of a patients health and applying analytics and machine learning to improve care, analyze population health trends, and improve operational efficiency. However, clinical data is complex and renowned for being siloed, incomplete, incompatible, and stored in on-premises systems spread across multiple locations. Getting all this information aggregated and in the FHIR format is a start toward the goal of standardizing structured data, but the majority of data remains unstructured and still needs to be tagged, indexed, and structured in chronological order to make all of the data understandable and able to query. Some healthcare organizations build rule-based tools to automate the process of transforming unstructured data (e.g., medical histories, physician notes, and medical imaging reports) and tagging clinical information (e.g., diagnoses, medications, and procedures), but these solutions often fail because the data needs to be normalized across disparate systems and because the tools cant account for every possible variation in spelling, unintended typos, and grammatical errors. Other organizations use general-purpose optical character recognition (OCR) software to process data sources, but these tools lack the medical expertise to be effective and so organizations resort to manual data entry by medical professionals which adds expense to the digitization process. Even if organizations are able to aggregate and structure their data, they still need to build their own analytics and machine learning applications to uncover relationships in the data, discover trends, and make precise predictions. The cost and operational complexity of doing all this work is prohibitive to most organizations; and as a result, the vast majority of organizations end up missing out on the untapped potential to use their data to improve the health of patients and communities.

Amazon HealthLake offers medical providers, health insurers, and pharmaceutical companies a service that brings together and makes sense of all their patient data, so healthcare organizations can make more precise predictions about the health of patients and populations. The new HIPAA-eligible service enables organizations to store, tag, index, standardize, query, and apply machine learning to analyze data at petabyte scale in the cloud. Amazon HealthLake allows organizations to easily copy health data from on-premises systems to a secure data lake in the cloud and normalize every patient record across disparate formats automatically. Upon ingestion, Amazon HealthLake uses machine learning trained to understand medical terminology to identify and tag each piece of clinical information, index events into a timeline view, and enrich the data with standardized labels (e.g., medications, conditions, diagnoses, procedures, etc.) so all this information can be easily searched. For example, organizations can quickly and accurately find answers to their questions like, How has the use of cholesterol-lowering medications helped our patients with high blood pressure last year? To do this, customers can create a list of patients by selecting High Cholesterol from a standard list of medical conditions, Oral Drugs from a menu of treatments, and blood pressure values from the Blood Pressure structured field and then they can further refine the list by choosing attributes like time frame, gender, and age. Because Amazon HealthLake also automatically structures all of a healthcare organizations data into the FHIR industry format, the information can be easily and securely shared between health systems and with third-party applications, enabling providers to collaborate more effectively and allowing patients unfettered access to their medical information.

There has been an explosion of digitized health data in recent years with the advent of electronic medical records, but organizations are telling us that unlocking the value from this information using technology like machine learning is still challenging and riddled with barriers, said Swami Sivasubramanian, Vice President of Amazon Machine Learning for AWS. With Amazon HealthLake, healthcare organizations can reduce the time it takes to transform health data in the cloud from weeks to minutes so that it can be analyzed securely, even at petabyte scale. This completely reinvents whats possible with healthcare and brings us that much closer to everyones goal of providing patients with more personalized and predictive treatment for individuals and across entire populations.

By aggregating, labeling, indexing, and structuring all their data, Amazon HealthLake makes it easy for customers to query, analyze, and use machine learning to make sense of their data. Customers can use other AWS analytics and machine learning services with Amazon HealthLake like Amazon QuickSight for interactive dashboards and Amazon SageMaker for easily building, training, and deploying custom machine learning models. For example, healthcare organizations can use Jupyter Notebook templates in Amazon SageMaker to quickly and easily run analysis for common tasks like diagnosis predictions, hospital re-admittance probability, and operating room utilization forecasts. Healthcare and life science organizations can use Amazon HealthLake to get a complete view of patient and population health, derive insights using analytics and machine learning, and discover previously obscured relationships and trends.

Cerner Corporation, a global healthcare technology company, is focused on using data to help solve issues at the speed of innovation - evolving healthcare to enhance clinical and operational outcomes, help resolve clinician burnout, and improve health equity. "At Cerner we are committed to transforming the future of healthcare through cloud delivery, machine learning, and AI. Working alongside AWS, we are in a position to accelerate innovation in healthcare. That starts with data. We are excited about the launch of Amazon HealthLake and its potential to quickly ingest patient data from various diverse sources and transform the data to perform advanced analytics to unlock new insights and serve many of our initiatives across population health, said Ryan Hamilton, SVP, Population Health, Cerner.

Ciox Health is a health technology company that is dedicated to improving U.S. health outcomes by transforming clinical data into actionable insights. At Ciox, we work to enable greater health by improving the way health information is managed, said Sasidhar Mukkamala, SVP of Data Management, Ciox Health. Much of the health information that we ingest is unstructured, like notes and handwritten PDFs, and it is a challenge to find solutions that allow us to realize the full analytic value of that data. With 60 percent of the market share in risk adjustments, this is a huge opportunity. We are excited about getting started with Amazon HealthLake and its potential to help us meet this need and deliver better risk adjustments, predictions, billing, and much more, all informed by health data.

Konica Minolta Precision Medicine (KMPM) is a life science company dedicated to the advancement of precision medicine to more accurately predict, detect, treat, and ultimately cure disease. "We are building a multi-modal platform at KMPM to handle a significant amount of health data inclusive of pathology, imaging, and genetic information. Amazon HealthLake will allow us to unlock the real power of this multi-modal approach to find novel associations and signals in our data. It will provide our expert team of data scientists and developers the ability to integrate, label, and structure this data faster, and discover insights that our clinicians and pharmaceutical partners require to truly drive precision medicine," said Kiyotaka Fujii, President of Global Healthcare, Konica Minolta.

Orion Health is a global, award-winning provider of health information technology, advancing population health and precision medicine solutions for the delivery of care across the entire health ecosystem. At Orion Health, we believe that there is significant untapped potential to transform the healthcare sector by improving how technology is used and providing insights into the data being generated. We are pleased to find a like-minded company in AWS who, with Amazon HealthLake, is now taking the next step in using machine learning to help make sense of health data in a secure, complaint, and auditable way, said Anne O'Hanlon, Product Director, Orion Health. Data is frequently messy and incomplete, which is costly and time consuming to clean up. We are excited to work alongside AWS to deliver new ways for patients to interact with the healthcare system, supporting initiatives such as the 21st Century Cures Act designed to make healthcare more accessible and affordable, and Digital Front Door, which aims to improve health outcomes by helping patients receive the perfect care for them from the comfort of their home. Expanding the relationship we enjoy with AWS gives us an opportunity to innovate and explore new ways to deliver patient-centered healthcare and high quality health outcomes that help people live a healthier life.

About Amazon Web Services

For 14 years, Amazon Web Services has been the worlds most comprehensive and broadly adopted cloud platform. AWS offers over 175 fully featured services for compute, storage, databases, networking, analytics, robotics, machine learning and artificial intelligence (AI), Internet of Things (IoT), mobile, security, hybrid, virtual and augmented reality (VR and AR), media, and application development, deployment, and management from 77 Availability Zones (AZs) within 24 geographic regions, with announced plans for 18 more Availability Zones and six more AWS Regions in Australia, India, Indonesia, Japan, Spain, and Switzerland. Millions of customersincluding the fastest-growing startups, largest enterprises, and leading government agenciestrust AWS to power their infrastructure, become more agile, and lower costs. To learn more about AWS, visit aws.amazon.com.

About Amazon

Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Fire tablets, Fire TV, Amazon Echo, and Alexa are some of the products and services pioneered by Amazon. For more information, visit amazon.com/about and follow @AmazonNews.

Originally posted here:
AWS Announces Amazon HealthLake - Business Wire

As the precision medicine field evolves and the science behind personalized therapies for complex conditions surges ahead, reimbursement models are racing to catch up. Precision medicine treatments, like cell and gene therapies, tend to have high price tags and novel delivery mechanisms. This makes creating effective payment models for these therapies a challenge, but drug developers and payers are working together to create out-of-the-box solutions.

Determining prices for breakthrough cell and gene therapies is a complicated process, said Laura Okpala, director of reimbursement policy at Gilead Sciences, at the MedCity INVEST Precision Medicine conference. Though there is a strong belief that the pricing process needs to be driven by value value means different things to different people. Biopharmaceutical companies, like Gilead Sciences, must consult with various stakeholders, including patients, caregivers and payers, who all have different perspectives on value.

Part of why the pricing is so difficult is because of the inherent complexities in the healthcare system, Okpala said. When we think of traditionally how drugs are paid for, were thinking about chronic treatment, were thinking about treatment over a long, extended period, treatment over and over again, reimbursement every single time, and that adds up.

But when you think about cell and gene therapies, all those costs and all of that treatment happens upfront, she added. And then you get that durable response, up to four years at this point. And that is really a paradigm shift when you think about [a] healthcare system that really isnt set up to deal with that upfront cost and that value delivered over time.

But the upfront payment is just one of many challenges. Mark Trusheim, strategic director of the NEWDIGS initiative at the MIT Center for Biomedical Innovation, said at the virtual conference that there are two more key challenges that arise: the performance uncertainty regarding these therapies, particularly around their durability, and the actuarial uncertainty it causes for payers. Most of these therapies are for rare conditions, so a single high-cost therapy in any given month can have a negative impact on payers income statements.

To combat these challenges, several innovative reimbursement models have been developed.

One is a model based on treatment milestones. Per this model, a certain amount of money is paid upfront, and if the therapy doesnt show the intended effects in certain predetermined timeframes, the drug developer pays back a portion of the initial payment.

[The model allows] some risk sharing between the developer and the payer, so they dont have to argue quite so much up front, Trusheim said. And the actual product performance [resolves] how much [is] finally the net reimbursement or the net price for that therapy.

This model helps manage the different expectations and fears of both parties, he added.

Another is a subscription-based model, which includes a fixed fee for unlimited access to certain therapies, Trusheim explained. Cigna has an insurance product that offers this reimbursement model, where plan members contribute a certain amount each month that is used to pay for therapies as needed. Cigna takes on the risk, guaranteeing that they will provide as much therapy as the members require.

This model is a great example of how payers can manage the actuarial fluctuation that occurs when funding cell and gene therapies, Trusheim said. But it comes with its challenges, because in some cases, its difficult to ascertain the eligible population for a particular therapy especially if there are alternate therapies already available.

But Trusheim is confident that innovation in reimbursement will catch up to clinical innovation in the precision medicine arena.

Were now in an era where innovation in payment structures and approaches are beginning to match the kind of innovation we have in the transformative science for patients, he said. Successfully providing patient access and benefit requires both kinds of innovation, not just scientific innovation. The creativity is there we are going to succeed. Just as the science has succeeded, the payment innovation is also moving forward and having success.

Photo credit: Devrimb, Getty Images

View post:
Innovative payment models to support cell and gene therapies on the rise - MedCity News

Newswise PLYMOUTH MEETING, PA [December 10, 2020] Today, the National Comprehensive Cancer Network (NCCN) hosted an annual patient advocacy summit featuring Senator Chris Van Hollen (D-MD) and Congressman Buddy Carter (R-GA), which was streamed online. Every year, the NCCN Policy department invites people from across the oncology ecosystem to share their perspectives on improving the quality and efficiency of cancer care so that patients can live better lives. This years virtual summit focused on putting the personal into personalized care while exploring how the needs of people with cancer can vary across the lifespan.

We work with patient advocacy organizations year-round to ensure our policy team is advocating for policies that address the most pressing issues for people with cancer and their caregivers, said Alyssa Schatz, MSW, Senior Director of Policy and Advocacy for NCCN and a participant in the roundtable discussion titled Identifying Policy and Practice Solutions for Patients Across the Lifespan. This summit gives us a chance to learn from one another and speak collectively to our audience of providers, payers, and policymakers. A key takeaway from todays conversation is the reminder to treat the personnot the demographicwhile also recognizing that people in some demographics may face additional obstacles to quality cancer care.

Cancer survivors are more than their age, gender, or disease, explained keynote speaker Jan S. White, Cancer Survivor and Patient Advocate. Assumptions around age and gender often figure into care teams expectations for survivorship, but if you have not asked your patients about their goals for how they want to live following treatment, you are missing an important step. Their answers will surprise you.

The idea of recognizing everyones unique set of circumstances was echoed by Danielle Pardue, a panelist who spoke on behalf of caregivers: The best way to support a caregiver is to take the time to understand the individual needs and strengths of each caregiver and patient. No plan of care for any patient can be completely successful without the support of one or more caregivers, especially at home. Providers need to take both the patients preferences and the caregivers abilities into account when determining their treatment recommendations.

Pardue also pointed out: Every problem does not necessarily have a solution; caregivers should be encouraged to share what they need so that solutions can be sought, but shouldnt be discouraged from sharing when solutions are hard to come by. Sharing experiences is in itself a therapeutic experience for overwhelmed caregivers. There is great power and healing in venting because we understand the world through the stories of others.

Speakers also looked at how members of various racial, ethnic, or socioeconomic groups can face some common or recurring barriers to care that must be addressed.

We cannot separate social, racial, and economic inequality from the adult cancer journey, said Darcie Green, Executive Director of Latinas Contra Cancer. The clients we serve face predictable and preventable systemic barriers to cancer care. Navigating cancer can be challenging enough without also having to worry about how you will feed your family, pay rent, absorb income loss, or overcome the obstacles that exist within the healthcare system. The COVID-19 pandemic has only deepened health injustice and the trauma of poverty in this country. This impact is reflected in the experience of cancer patients in the population we serve.

Many of the speakers focused particularly on how a persons age at the time of diagnosis can result in different options or approaches for treatment, for instance older patients, who are more-likely to have additional, unrelated health concerns, or may face implicit bias based on their age.

As we refine our understanding of tumor biology and tailor therapy to the molecular subtype of each tumor, we must remember factors outside of the actual treatment that significantly affect outcomes, observed Efrat Dotan, MD, Fox Chase Cancer Center, Chair of the NCCN Guidelines Panel for Older Adult Oncology. Especially when treating older adults with cancer, evaluating all the domains that affect their careand addressing any deficiencieswill result in truly personalized medicine and improved outcomes.

Cancer is a disease of aging, yet older patients have not shared in the benefits of many modern cancer treatments, and remain woefully underrepresented in clinical trials, said Hyman Muss, MD, FASCO, University of North Carolina Lineberger Comprehensive Cancer Center. It is the obligation of all of us to fix this in order to guarantee that our older cancer patients get the care they need.

We know how important it is to make sure clinical trials enroll a broad representation of patients across age, race, and ethnicity, agreed Maura Dickler, MD, Lilly Oncology. At Lilly, we are committed to reducing the barriers that limit diversity in clinical trial enrollment, including working to ensure our trial sites are closer to patients, utilizing new forms of telehealth when appropriate, and broadening eligibility criteria so we are not excluding patients who have additional health conditions.

There are also unique concerns for cancer survivors who were first diagnosed during childhood or adolescence. Panelists discussed the confusion that can arise over what happens once patients complete active treatment. Thats where survivorship care plans and clinical practice guidelines on preventing or managing recurrence and side effects can play an important role.

Effective transition of care in cancer survivors from oncologists to primary care physicians can make a significant difference in early detection of late effects. You can't find something that you are not looking for, saidAarati Didwania, MD, MSCI, Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Speakers at the summit also touched on current events impacting cancer care including the upcoming Supreme Court ruling on the Affordable Care Act and the long- and short-term impact of the COVID-19 pandemic on cancer care. The virtual discussions were moderated by Clifford Goodman, PhD, The Lewin Group, and also included Phylicia L. Woods, JD, MSW, from the Cancer Support Community.

Representatives from the Cancer Hope Network, Patient Empowerment Network, and Fight Colorectal Cancer presented information about age-specific resources intended to increase access to recommended screening, improve health literacy, and provide peer-to-peer counseling services. Dottie Shead, MS, from NCCNs patient information department discussed existing NCCN Guidelines for Patients across cancer types and supportive care topics, including symptom management and age-related care for adolescents and young adults. Shead also previewed the soon-to-publish patient and caregiver guidelines focused specifically on survivorship, including guidance on post-treatment wellness recommendations, and monitoring and treating the late and long-term effects that can arise from cancer care.

Visit NCCN.org/patients to learn more about free resources from NCCN. Visit NCCN.org/policy for more on the ongoing work from the NCCN Policy and Advocacy Department and save-the-date for future summits and events. Join the conversation online using the hashtag #NCCNPolicy.

# # #

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information and follow NCCN on Facebook @NCCNorg, Instagram @NCCNorg, and Twitter @NCCN.

Original post:
NCCN Patient Advocacy Summit Emphasizes Treating Every Cancer Patient as an Individual - Newswise

DUBLIN--(BUSINESS WIRE)--The "Global Next Generation Sequencing Market: Growth, Trends, Competitive Landscape, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

The global next-generation sequencing market is expected to grow at a CAGR of around 17.5% during 2020-2026.

Next-generation sequencing is also known as high-throughput sequencing. It is the process of determining the sequence of nucleotides in a section of the DNA. It includes procedures such as sequencing by ion semiconductor sequencing, synthesis (SBS), nanopore sequencing and single-molecule real-time (SMRT) sequencing. It is a cost-effective solution that offers precise results with high accuracy and speed. This enables the analysis of millions of DNA molecules simultaneously, which facilitates research in the fields of personalized and genetic medicines, agriculture and animal research, and clinical diagnostics.

The global next-generation sequencing market report elucidates key industry trends, industry dynamics along with the quantitative analysis of the report. The report presents a clear picture of the global next-generation sequencing market by segmenting the market based on sequencing type, product type, technology, application, end user, and region. We believe that this report will aid the professionals and industry stakeholders in making informed decision.

Market Dynamics

Drivers

Challenges

Companies Mentioned

Key Topics Covered:

1. Preface

2. Executive Summary

3. Global Next Generation Sequencing Market

3.1 Introduction

3.2 Market Drivers & Challenges

4. Global Next Generation Sequencing Market Analysis

4.1 Market Portraiture

4.2 Market by Sequencing Type

4.3 Market by Product Type

4.4 Market by Technology

4.5 Market by Application

4.6 Market by End User

4.7 Market by Region

4.8 Impact of COVID-19

5. Global Next Generation Sequencing Market by Sequencing Type

5.1 Market Overview

5.2 Whole Genome Sequencing

5.3 Targeted Resequencing

5.4 Whole Exome Sequencing

5.5 RNA Sequencing

5.6 CHIP Sequencing

5.7 De Novo Sequencing

5.8 Methyl Sequencing

5.9 Others

6. Global Next Generation Sequencing Market by Product Type

6.1 Market Overview

6.2 Instruments

6.3 Reagents and Consumables

6.4 Software and Services

6.5 Others

7. Global Next Generation Sequencing Market by Technology Type

7.1 Market Overview

7.2 Sequencing by Synthesis

7.3 Ion Semiconductor Sequencing

7.4 Single-Molecule Real-Time Sequencing

7.5 Nanopore Sequencing

7.6 Others

8. Global Next Generation Sequencing Market by Application

8.1 Market Overview

8.2 Drug Discovery and Personalized Medicine

8.3 Genetic Screening

8.4 Diagnostics

8.5 Agriculture and Animal Research

8.6 Bioinformatics

8.7 Others

9. Global Next Generation Sequencing Market by End User

9.1 Market Overview

9.2 Academic Institutes & Research Centers

9.3 Hospitals & Clinics

9.4 Pharmaceutical & Biotechnology Companies

9.5 Others

10. Global Next Generation Sequencing Market by Region

10.1 Market Overview

10.2 Europe

10.3 North America

10.4 Asia Pacific

10.5 Latin America

10.6 Middle East & Africa

11. SWOT Analysis

12. Porter's Five Forces

13. Market Value Chain Analysis

14. Competitive Landscape

14.1 Competitive Scenario

14.2 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/hjtnq5

Link:
The Worldwide Next Generation Sequencing Industry is Expected to Grow at a CAGR of 17.5% Between 2020 and 2026 - ResearchAndMarkets.com - Business...

DUBLIN--(BUSINESS WIRE)--The "Spectroscopy Equipment and Accessories - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Global Spectroscopy Equipment and Accessories Market to Reach $16.5 Billion by 2027

Amid the COVID-19 crisis, the global market for Spectroscopy Equipment and Accessories estimated at US$14.6 Billion in the year 2020, is projected to reach a revised size of US$16.5 Billion by 2027, growing at a CAGR of 1.8% over the analysis period 2020-2027.

Molecular Spectroscopy, one of the segments analyzed in the report, is projected to record a 2.1% CAGR and reach US$5.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Atomic Spectroscopy segment is readjusted to a revised 1.3% CAGR for the next 7-year period.

The U. S. Market is Estimated at $4 Billion, While China is Forecast to Grow at 3.6% CAGR

The Spectroscopy Equipment and Accessories market in the U. S. is estimated at US$4 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.2 Billion by the year 2027 trailing a CAGR of 3.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 0.2% and 1.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 0.7% CAGR.

Mass Spectrometry Segment to Record 2.1% CAGR

In the global Mass Spectrometry segment, USA, Canada, Japan, China and Europe will drive the 1.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$3 Billion in the year 2020 will reach a projected size of US$3.4 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$2.2 Billion by the year 2027, while Latin America will expand at a 2.8% CAGR through the analysis period.

The report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Key Topics Covered:

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/hbdoxf

See the original post:
Global Spectroscopy Equipment and Accessories Market Report 2020-2027: Molecular Spectroscopy to Account for $5.8 Billion of the $16.5 Billion Market...

Medicine has always been personalized what has changed are the tools available that allow us to provide better care for you. The Institute for Personalized Medicine is Penn State Health's commitment to advancing health care for our community through the use of modern technology and more effective tools.

In the past, doctors based treatments on research that studied broad groups of people, finding what is most likely to help a majority of patients. While this approach has been successful, its not always efficient since each of us is different. Our genetics and our biology are unique to us, so treatments that work best for one person may not work best for another.

Personalized medicine is the use of individual characteristics to tailor treatments to the person. For example, one person may respond to a medicine differently than another because of their genetics. By knowing what that genetic difference is, doctors can look for the same in future patients and prescribe medication accordingly helping to recover faster.

Penn State Institute for Personalized Medicine gives scientists the tools to develop research studies seeking this information, and future therapies for patients.

Continue reading here:
Personalized Medicine | Penn State Health

DUBLIN, Nov. 11, 2020 /PRNewswire/ -- The "Personalized Medicine - Scientific & Commercial Aspects" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

The concept of personalized medicine described in this report remains remains the best way to integrate new technologies such as nanobiotechnology for improving healthcare.

Increase in efficacy and safety of treatment by individualizing it has benefits in financial terms. Information is presented to show that personalized medicine will be cost-effective in healthcare systems. For the pharmaceutical companies, segmentation of the market may not leave room for conventional blockbusters but smaller and exclusive markets for personalized medicines would be profitable. Marketing opportunities for such a system are described with market estimates from 2019-2029.

Profiles of 298 companies involved in developing technologies for personalized medicines, along with 583 collaborations are included.The aim of personalized medicine or individualized treatment is to match the right drug to the right patient and, in some cases, even to design the appropriate treatment for a patient according to his/her genotype. This report describes the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics,pharmacoproteomics, and metabolomics.

Basic technologies of molecular diagnostics play an important role, particularly those for single nucleotide polymorphism (SNP) genotyping. Biomarkers play an important role in personalized medicine. Diagnosis is integrated with therapy for selection of treatment as well for monitoring the results. There is emphasis on early detection and prevention of disease in modern medicine. Biochip/microarray technologies and next generation sequencing are also important.

Pharmacogenetics, the study of influence of genetic factors on drug action and metabolism, is used for predicting adverse reactions of drugs. Several enzymes are involved in drug metabolism of which the most important ones are those belonging to the family of cytochrome P450. The knowledge of the effects of polymorphisms of genes for the enzymes is applied in drug discovery and development as well as in clinical use of drugs. Cost-effective methods for genotyping are being developed and it would be desirable to include this information in the patient's record for the guidance of the physician to individualize the treatment.

Pharmacogenomics, a term that overlaps with pharmacogenetics but is distinct, deals with the application of genomics to drug discovery and development. It involves the mechanism of action of drugs on cells as revealed by gene expression patterns. Pharmacoproteomics is an important contribution to personalized medicine as it is a more functional representation of patient-to-patient variation than that provided by genotyping.A 'pharmacometabonomic' approach to personalizing drug treatment is also described.

Story continues

Biological therapies such as those which use patient's own cells are considered to be personalized medicines. Vaccines are prepared from individual patient's tumor cells. Individualized therapeutic strategies using monoclonal bodies can be directed at specific genetic and immunologic targets. Ex vivo gene therapy involves the genetic modification of the patient's cells in vitro, prior to reimplantation of these cells in the patient's body.

Various technologies are integrated to develop personalized therapies for specific therapeutic areas described in the report. Examples of this are genotyping for drug resistance in HIV infection, personalized therapy of cancer, antipsychotics for schizophrenia, antidepressant therapy, antihypertensive therapy and personalized approach to neurological disorders. Although genotyping is not yet a part of clinically accepted routine, it is expected to have this status by the year 2023.

Several players are involved in the development of personalized therapy. Pharmaceutical and biotechnology companies have taken a leading role in this venture in keeping with their future role as healthcare enterprises rather than mere developers of technologies and manufacturers of medicines.

Ethical issues are involved in the development of personalized medicine mainly in the area of genetic testing. These along with social issues and consideration of race in the development of personalized medicine are discussed. Regulatory issues are discussed mainly with reference to the FDA guidelines on pharmacogenomics.

Finally the bibliography contains over 750 selected publications cited in the report. The report is supplemented by 88 tables and 50 figures.

Key Topics Covered:

Part I: Scientific Basis & Technologies

Executive Summary

1. Basic Aspects

2. Molecular Diagnostics in Personalized Medicine

3. Pharmacogenetics

4. Pharmacogenomics

5. Role of Pharmacoproteomics

6. Role of Metabolomics in Personalized Medicine

7. Personalized Biological Therapies

8. Personalized complementary & Alternative Therapies

9. Personalized Medicine in Major Therapeutic Areas

10. Personalized Therapy of Cancer

11. Development of Personalized Medicine

12. Ethical, Legal and Regulatory Aspects of Personalized Medicine

Part II: Markets & Companies

13. Markets for Personalized Medicine

14. Companies Involved in Developing Personalized Medicine

15. References

For more information about this report visit https://www.researchandmarkets.com/r/ty8o34

Source: Jain PharmaBiotech

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/personalized-medicine-market-2029-301170831.html

SOURCE Research and Markets

Read more here:
Personalized Medicine Market, 2029

LONDON--(BUSINESS WIRE)--The global biochip market size is poised to grow by USD 19.71 billion during 2020-2024, progressing at a CAGR of 22% throughout the forecast period, according to the latest report by Technavio. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. The report also provides the market impact and new opportunities created due to the COVID-19 pandemic. Download a Free Sample of REPORT with COVID-19 Crisis and Recovery Analysis.

Personalized medicines growing popularity and demand is expected to drive the growth of the Biochip market. The medicines are personalized as per the patients needs which suits the individual characteristics of the person is a multi-faceted approach. This improves the ability to diagnose and effectively treat the disease as this technique facilitates early diagnosis. These biochips play an important part in the development of these medicines, as it improves the ability to diagnose and effectively treat the disease. It is also expected that during the forecast period the growing incidences of genetic and terminal diseases will influence the demand for personalized medicine for targeted drug development. This will increase the demand for biochips which will result in the growth of this industry.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Report Highlights:

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Rising Use of Biochips in Safety Detection of Agriculture Products will be a Key Market Trend

The rising use of biochip technology in the agriculture industry is turning out to be one of the major trends in the biochip industry. Biochip helps in the detection of pathogenic microorganisms, biological toxins, pesticide residues, and antibiotics. Microchips help in providing early warning to agricultural products' monitoring with a rapid response system and, thus, enhance the agricultural products' safety detection system. Therefore, significantly helping the agriculture industry from the loss it faces every year.

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Biochip Market 2020-2024: Key Highlights

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Technology

Customer landscape

Geographic Landscape

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Read the original post:
Biochip Market | Increased Popularity of Personalized Medicine to Boost the Market Growth | Technavio - Business Wire

THE HAGUE, Netherlands, Dec. 5, 2020 /PRNewswire/ --The HARMONY Alliance announces new analyses demonstrating how Big Data can facilitate personalized medicine in patients with blood cancers, also known as Hematologic Malignancies. Using data from around 12,000 AML and MM patients comprised in the HARMONY Big Data Platform, the researchersobtained fascinating insights into the molecular basis of Acute Myeloid Leukemia (AML) and developed an improved risk stratification model for Multiple Myeloma (MM). These results are presented during the 62nd American Society of Hematology Annual Meeting.

Harmony Alliance Provides Novel Insights into Acute Myeloid Leukemia Based on a Pan-European NGS Data Collection (abstract 1077- Bullinger et al)

Lars Bullinger, HARMONY Partner Charit Berlin, Germany:

"We have analyzed genomic data of 4,986 patients with AML. We could confirm the co-occurrence of certain mutations. In addition, we obtained insight into which mutations occur first and which later in the disease process. We have also investigated the association of mutation patterns with clinical outcomes such as remission, relapse, and survival. For instance, many patients with high-risk mutation patterns benefit only little from an allogeneic stem cell transplantation (alloSCT), but we found specific high-risk genotype combinations that predict a much larger survival benefit."

A New Risk Stratification Model (R2-ISS) in Newly Diagnosed Multiple Myeloma: Analysis of Mature Data from 7,077 Patients Collected By European Myeloma Network within Harmony Big Data Platform (abstract 1329- D'Agostino et al)

Mattia D'Agostino, HARMONY Partner University of Turin, Italy:

"Clinical outcomes for patients with MM vary greatly, with survival ranging from a few months to more than ten years. Investigating data from 7,077 patients with newly diagnosed MM, we discovered that patients who are currently considered as 'intermediate-risk patients' constitute a quite diverse group with varying risk of progression or death. We identified a new prognostic system identifying 4 risk classes. With this model, about half of the patients can be classified as low or low-intermediate risk, and about half of them can be classified as intermediate-high or high risk. Oncologists can use our improved risk stratification model to better estimate patients' prognosis at the time of MM diagnosis. Moreover, this model favors the design of MM treatments tailored according to the individual risk of each patient."

Comprising data from 45,000 patients with blood cancers, makes the HARMONY Big Data Platform one of the largest of its kind in the world. HARMONY scientists use the Platform to characterize the molecular landscape of Hematologic Malignancies, understand their pathophysiology, and identify novel drug targets. Big data analytics has the potential to transform the treatment of patients with blood cancers. The ability to personalize the treatment of a patient based on molecular understanding of a disease or risk stratification will provide treatment strategies in the future to optimize outcomes for the patients.

More information

SOURCE HARMONY Alliance

https://www.harmony-alliance.eu

Original post:
New data from HARMONY demonstrate the power of Big Data analytics to inform personalized medicine in blood cancer - PRNewswire

News Release

Friday, December 4, 2020

Previously unknown genetic connection could be a target for gene therapy.

A study led by researchers at the National Institutes of Health has made a surprising connection between frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), two disorders of the nervous system, and the genetic mutation normally understood to cause Huntingtons disease.

This large, international project, which included a collaboration between the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), opens a potentially new avenue for diagnosing and treating some individuals with FTD or ALS.

Several neurological disorders have been linked to repeat expansions, a type of mutation that results in abnormal repetition of certain DNA building blocks. For example, Huntingtons disease occurs when a sequence of three DNA building blocks that make up the gene for a protein called huntingtin repeats many more times than normal. These repeats can be used to predict whether someone will develop the illness and even when their symptoms are likely to appear, because the more repeats in the gene, the earlier the onset of disease.

It has been recognized for some time that repeat expansion mutations can give rise to neurological disorders, said Sonja Scholz, M.D., Ph.D., investigator, NINDS Intramural Research Program. But screening for these mutations throughout the entire genome has traditionally been cost-prohibitive and technically challenging.

Taking advantage of technology available at NIH, the researchers screened the entire genomes from large cohorts of FTD/ALS patients and compared them to those of age-matched healthy individuals. While several patients had a well-established genetic marker for FTD/ALS, a small subset surprisingly had the same huntingtin mutation normally associated with Huntingtons disease. Remarkably, these individuals did not show the classical symptoms of Huntingtons but rather those of ALS or FTD.

None of these patients symptoms would have clued their physicians into thinking that the underlying genetic cause was related to the repeat expansion we see in Huntingtons disease, said Dr. Scholz.

She continued by explaining that whole genome sequencing is changing how neurological patients can be diagnosed. Traditionally, this has been based on which disease best fit the overall symptoms with treatment aimed at managing those symptoms as best as possible. Now, clinicians can generate genetically defined diagnoses for individual patients, and these do not always align with established symptom-based neurological conditions.

Our patients simply dont match a textbook definition of disease when it comes to which mutation produces which symptoms. Here we have patients carrying a pathogenic huntingtin mutation but who present with FTD or ALS symptoms, said Dr. Scholz.

One implication of these findings is that, if successful, these therapies could be applied to the small subset of FTD and ALS patients with that mutation as well. The researchers note that, while the number of FTD/ALS patients seen with the Huntingtons-linked mutation is small (roughly 0.12-0.14%), adding genetic screening for the mutation to the standard diagnostic procedure for patients showing symptoms of FTD or ALS should be considered.

Because gene therapy targeting this mutation is already in advanced clinical trials, our work offers real hope to the small number of FTD and ALS patients who carry this mutation, said Bryan Traynor, M.D., Ph.D., senior investigator, NIA Intramural Research Program. This type of large-scale international effort showcases the power of genomics in identifying the molecular causes of neurodegenerative diseases and paves the way for personalized medicine.

This research was supported by the Intramural Research Program of the National Institutes of Health (National Institute on Aging and National Institute of Neurological Disorders and Stroke; project numbers 1ZIAAG000935, 1ZIANS003154, 1ZIANS003033, 1ZIANS003034), the Intramural Research Program of the National

NINDSis the nations leading funder of research on the brain and nervous system.The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

About the National Institute on Aging (NIA): NIA leads the U.S. federal government effort to conduct and support research on aging and the health and well-being of older people. Learn more about age-related cognitive change and neurodegenerative diseases via NIAs Alzheimer's and related Dementias Education and Referral (ADEAR) Center website. For information about a broad range of aging topics, visit the main NIA website and stay connected.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

Dewan R. et al. Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Neuron. November 25, 2020. DOI:10.1016/j.neuron.2020.11.005

###

View original post here:
NIH researchers link cases of ALS and FTD to a mutation associated with Huntington's disease - National Institutes of Health

NEW YORK, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to personalized medicine and drug discovery, today announced that its virtual Special Meeting of Stockholders, scheduled for December 1, 2020, was convened and adjourned without any business being conducted due to the fact that quorum was not achieved. The Special Meeting will be reconvened December 30, 2020 at 3 p.m. CST and will be conducted via live audio webcast at http://www.virtualshareholdermeeting.com/POAI2020SM, so as to allow more opportunity for stockholders to vote on all proposals described in the Companys definitive proxy statement filed with the Securities and Exchange Commission (SEC) on November 3, 2020.

The record date for the Special Meeting remains October 28, 2020. Stockholders of record may vote at the reconvened Special Meeting, vote by proxy using the proxy card enclosed with the Companys definitive proxy statement, vote by proxy via facsimile, email or on the Internet. Whether or not stockholders of record plan to attend the reconvened Special Meeting, the Companys Board of Directors and management urge them to vote by proxy to ensure their vote is counted. Stockholders who have previously submitted their proxy or otherwise voted and who do not want to change their vote need not take any action.

A copy of the Companys proxy statement as previously filed with the SEC is available at no charge on the SEC website at http://www.sec.gov. In addition, copies of the proxy statement and other documents may be obtained free of charge by accessing the Companys website at https://investors.predictive-oncology.com/ or by contacting the Companys Corporate Secretary at (651) 389-4806 or by mail to Corporate Secretary, Predictive Oncology Inc., 2915 Commers Drive, Suite 900, Eagan, MN 55121.

YOUR PARTICIPATION IS IMPORTANT - PLEASE VOTE TODAY!

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.

Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes.

Forward-Looking Statements

Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words anticipate, believe, estimate, expect, intend, may, plan, would, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading Risk Factors in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.

Investor Relations Contact:

Hayden IRJames Carbonara(646)-755-7412

See the original post:
Predictive Oncology Announces Adjournment of Special Meeting - GlobeNewswire

The cell therapy technologies market is expected to gain immense growth opportunities through the forecast period of 2019-2029 owing to the rising influence of cell therapies across the life sciences sector. The overwhelming need for novel and enhanced therapies for a variety of diseases and disorders may bring extensive growth prospects for the cell therapy technologies market during the forecast period.

The increased funding by the government may also prove to be a great growth prospect for the cell therapy technologies market. The precision medicine sector is evolving at a rapid rate across the globe. In this, a patient is given personalized treatment and is useful in making more accurate decisions. Thus, this factor may boost the growth of the cell therapy technologies market.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6943

Cellular therapy is the transplantation of human cells to replace cells or tissues. This therapy can be used for treating various diseases and disorders. The evolution of cell therapy technologies is bringing immense advancements across the sector. This therapy is used mainly for nervous system disorders and cancer. The growing cases of these diseases may further invite promising growth.

On the basis of product, the cell therapy technologies market can be segmented into consumables, cell processing equipment, single-use equipment, other equipment, and systems and software. Based on cell type, the cell therapy technologies market can be classified into stem cells, T-cells, and other cells. Cell therapy technology is utilized expansively in biopharmaceutical and biotechnology companies and CROs, and research institutes and cell banks.

The enhancements in cell therapy technology research through immense investments from various sectors may invite prominent growth prospects for the cell therapy technologies market.

This report has extensive information on a plethora of aspects related to the growth of the cell therapy technologies market. The L.E.A.P mechanism applied by the researchers enables a 360-degree view of the cell therapy technologies market. The CXOs derive the perfect information that allows them to chalk out their business strategy accordingly. This report also has scrutinized information about the novel coronavirus outbreak and its effect on the cell therapy technologies market.

Cell Therapy Technologies Market: Competitive Insights

The cell therapy technologies market is highly fragmented. Numerous players are involved in intense competition for gaining a prominent position among the end-users. The players are also involved in expansion activities through mergers and acquisitions. Some well-entrenched players in the cell therapy technologies market are Danaher Corporation, CellGenix GmbH, IxCells Biotechnology, Wilson Wolf Corporation, SIRION Biotech GmbH, Dickinson and Company, and FUJIFILM Irvine Scientific.

Buy this Premium Report @ https://www.tmrresearch.com/checkout?rep_id=6943&ltype=S

Cell Therapy Technologies Market: COVID-19 Impact

The COVID-19 impact may offer bright opportunities for the cell therapy technologies market to gain growth. The rising transmission of COVID-19 has led to rapid research and development activities in terms of an effective drug or vaccine. Cell-based research and technologies play an important role in the discovery of vaccines. Hence, this aspect may bring expansive growth prospects for the cell therapy technologies market.

Cell Therapy Technologies Market: Regional Prospects

The cell therapy technologies market in North America may gain a dominant position throughout the forecast period of 2019-2029. The maximizing research and development activities across the region for a good COVID-19 vaccine may bring profitable growth for the cell therapy technologies market. Robust healthcare expenditure, rising disposable income, and growing healthcare awareness may invite promising growth.

Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6943

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

Rohit Bhisey

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

See more here:
Cell Therapy Technologies Market | Extensive Information on a Plethora of Aspects Related to the Growth of the Market - BioSpace

There may be nothing quite as gut-wrenching as sitting at the bedside of a loved one, watching helplessly as their life comes to an end. Perhaps the only thing more painful is when that loved one no longer recognizes you, slipping away not knowing who it was holding their hand.

November is deemed Alzheimers Awareness Month. Though with the degenerative brain disease now affecting roughly 5.8 million Americans and their families today, its perhaps not so much an increase of awareness thats needed, but rather a desperate need for effective treatment.

Alzheimers is the only disease among the top 10 causes of death in America that cannot be prevented, cured or even slowed. Over a decade and billions of dollars have been spent on research to find a cure for Alzheimers, yet none have thus far proved real clinical benefit. If the elusive cure for Alzheimers isnt found soon, scientists estimate that by 2050 someone in the United States will develop the disease every 33 seconds.

While these statistics paint a pretty bleak picture, Cynthia Lemere, Ph.D., Associate Professor of Neurology at Brigham and Womens Hospital and Harvard Medical School, assured BioSpace that hope is not lost. Despite the many failed drug trials, Lemere says the horizon is finally looking optimistic and expects to see multiple treatments approved within the next few years.

Any therapy developed at this point is going to be probably good for one subsection of that 5.8 million people with Alzheimers disease. And maybe not even that population, but maybe the population that doesnt yet have Alzheimers disease but has the changes going on in their brain of Alzheimers, so we know that theyre on the track, Lemere said.

While no real treatment is yet approved, diagnostic capabilities have grown exponentially. When Lemere first started in the neurology field, a true Alzheimers diagnosis couldnt be given until autopsy. The past decade has shown that the pathology of the disease starts in the brain roughly 20 years before clinical symptoms. PET scans can determine those on a trajectory to develop Alzheimers and with new biomarker testing working towards FDA approval, theyll be able to predict onset of clinical symptoms.

Knowing those who are most likely to develop this degenerative brain disease and when opens opportunities for clinical trials that are in the works. The majority of treatments being developed right now are targeting that window before cognitive decline. There are currently 2,050 interventional studies listed on clinicaltrials.gov around the world for the treatment of AD.

One buzzworthy drug in the news is Biogens aducanumab. Back in March 2019, Biogen stopped two Phase III trials for the antibody drug based on an interim futility analysis that indicated a lack of efficacy. But after a full collection of their data, Biogen found there was indeed efficacy in the higher dosage group who received over 10 doses.

This left them with two very different sets of trial results EMERGE with a positive reading and ENGAGE with a negative. Lemere believes the evidence in the EMERGE trial was strong enough to show positive clinical benefits. Despite much criticism and doubts surrounding aducanumab, Biogen took it to the FDA with hopes for approval and received a harsh vote from an independent advisory committee. No word yet from the FDA. Lemere predicts the FDA will call for another, large Phase III study to confirm the positive result at the higher dose for the full study. Lemere consults with Biogen for the companys Alzheimers education program and is not involved with their drug development programs.

The main breakthrough in the past year for pharmaceutical treatment of AD is that researchers finally know what the right target is - a toxic amyloid oligomer formation that is a key driver for the disease. Biogen isnt the only one targeting it with their drug candidates. Also in the race are Alzheon with ALZ-801, Eisais BAN2401 and Roches gantenerumab.

Unlike the intravenous antibody candidates from the other three, Alzheons ALZ-801 is an orally administered amyloid oligomer inhibitor. Alzheon recently dosed their first patients in a Phase II biomarker study in APOE4 carriers. Patients with an APOE4 gene are at a much higher risk for developing Alzheimers, particularly if you were passed two of the genes. In August, the National Institute of Aging awarded Alzheon an unprecedented $47 million grant to assist with a Phase III clinical trial of ALZ-801. The trial is slated to start at the beginning of next year with a timeline of 2-3 years to complete. This Phase III will be dosing younger people with Alzheimers pathology to test for primary prevention, intervening before clinical symptoms appear.

A Shanghai-based biotech is targeting AD in a completely different way. Instead of targeting amyloid in the brain, Green Valleys candidate is going after the gut. GV-971 is an oral capsule with its primary ingredient derived from seaweed to therapeutically harnesses the abnormal production of amino acids, infiltration of immune cells to the brain, and in turn neuroinflammation via remodeling the gut microbiota. Reactions to this approach range from excitement to cautious optimism to downright skepticism. Time should soon tell if theres something to this approach as Green Valley has now identified its first patient for its Phase III trial in the US with the initial dose coming soon.

Drug developers arent the only ones trying to stop the devastating progression of AD. A research team at MIT found that in Alzheimer's mouse models, the right brain waves can drive microglia, scavenger cells that remove damaged neurons and infections in the central nervous system, to consume the toxic amyloid protein deposits. More research is being done in this area to explore this as a potential option for treatment in humans to reduce amyloid deposits in the brain.

Lemere listed off multiple research projects in the works for Alzheimers prevention therapies to prevent free-radical formation and reduce oxidative stress in the brain, studies into the importance of vascular health and its impact on AD, the effects of diet and exercise, and more. One study found significant results in patients using aggressive blood pressure therapy. People that had lowered their blood pressure and kept it around 120, compared to the control group hovering around 140, showed a significant slowing of the rate of visible cognitive impairment.

The Alzheimers Association, of which Lemere is a member of the medical and scientific advisory group, is sponsoring a lifestyle intervention study in the U.S. called POINTER, that takes into account exercise, nutrition, social interactions, cognitive stimulation and management of comorbidities to protect cognitive function in healthy older adults who are at an increased risk of cognitive decline.

The big point is that probably none of these is going to work by itself, Lemere said.

Rather she sees a future in which a doctor who sees Alzheimers pathology brewing in a patient will recommend a multi-prong defense.

I think its going to be a combination of treatments. And its not going to be the same combination for each person, Lemere said. Its going to be dependent on whatever else is going on with them. Because Alzheimers rarely occurs by itself. There are usually other comorbidities. So ultimately, I think it will be more personalized medicine and combination therapy.

In 2020 alone, the National Institutes of Health is expected to spend $2.8 billion on Alzheimers research. Costing the U.S. $277 billion a year, its the most expensive disease in America. Annual cost of care is projected to increase to $1.1 trillion by 2050. While the financial burden is exorbitantly high, for family members and caregivers its the emotional cost that leaves the deepest scars.

Arkansas resident Linda Crafton knows firsthand the devastating effects Alzheimers has on a family.

To me, its worst disease known to mankind. I used to think the way I lost my dad, which was an instant death, was the hardest way to lose someone, Crafton said. I now know that was wrong. The hardest way to lose your parent is day by day, little by little, an inch at a time.

Craftons mother and five of her mothers seven siblings were victims of the aggressive disease. She said shes in a generation of cousins who now live in fear of the future, wondering which of them will be the first to show the signs, the first to receive their own diagnosis.

Time magazine writer Jeffrey Kluger said, Suffering is always hard to quantify especially when the pain is caused by as cruel a disease as Alzheimer's. Most illnesses attack the body; Alzheimer's destroys the mind and, in the process, annihilates the very self.

Though a cure for Alzheimers has frustrated scientists for years, theyre closer now than theyve ever been before.

According to the Alzheimers Association, a lack of volunteers for clinical trials is one of the greatest obstacles slowing the progress of potential new treatments. If you or someone you love is on a trajectory for the development of Alzheimers disease, the association offers a free TrialMatch service to connect volunteers with clinical trials to advance research.

Most read today on BioSpace:

More:
Potential for an Alzheimer's Treatment Appears to Be Closer Than Ever - BioSpace

Latest launched research document on Pharma Clinical Trial Digitization Market study of 350 Pages provides detailed analysis with presentable graphs, charts and tables. This report covers a detailed study of the Pharma Clinical Trial Digitization Market size, growth, and share, trends, consumption, segments, application and Forecast 2027. The Research Study presents a complete assessment of the Market and highlights future trend, growth factors & drivers, leaders opinions, facts, and primary validated market data. The research study provides estimates for Pharma Clinical Trial Digitization Forecast till 2027. Pharma Clinical Trial Digitization Report is a comprehensive business study on the current state of industry which analyses innovative strategies for business growth and describes important factors such as top manufacturers, production value, key regions, and growth rate.

Download Free Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this Industry @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-pharma-clinical-trial-digitization-market&AB

Pharma Clinical Trial Digitization Market is accelerating owing to the demand of personalized medicine. The enhancement in the digital pharma services to keep the track of medication through the various components namely individualized drug printing, drug impact monitoring, bioprinting and others are defining the potential future of the pharma clinical trial digitization market during the forecast period of 2020 to 2027.

This upgradation of healthcare IT infrastructure and technological assistance being provided on vast scale is driving the market growth at the rate of 5.70% annual for the mentioned seven years. This momentum will be maintained by rising practice of individualized drug printing.

Pharma Clinical Trial Digitization Market report covers strategic profiling of key players in the market, comprehensively analyzing their core competencies, and their strategies such as new product launches, expansions, agreements, joint ventures, partnerships, and acquisitions which are applicable for the businesses with which they can take better steps to improve their strategies to sell goods and services. Market research study presents actionable market insights which help create sustainable and money-spinning business strategies. An absolute way to forecast what future holds is to comprehend the trend today. Thus, with this Pharma Clinical Trial Digitization business report, more important aspects of the Pharma Clinical Trial Digitization industry can be focused.

Pharma Clinical Trial Digitization Market Scenario

According to Data Bridge Market Research the Pharma Clinical Trial Digitization market is attaining a significant growth in the developing economies during the forecast period of 2020-2027 due to factors such as introduction of medical robots in hospitals, improving quality life of people, rising popularity of technologically advanced surgical robots and increasing diagnosis of diseases will boost the growth of the market. Pharma Clinical Trial Digitization Market is becoming more competitive every year with surgical robots will expect to attain maximum share during the period of 2020-2027. The Data bridge market research new reports highlight the major growth factors and opportunities in the Pharma Clinical Trial Digitization Market.

To Get the Short-Term and Long-Term Impact of COVID-19 on thisMarket@https://www.databridgemarketresearch.com/request-covid-19/global-pharma-clinical-trial-digitization-market&Ab

List of Significant Vendors Operating in this market include:

Antidote Technologies, Inc.AparitoClinerion Ltd.CliniOps, Inc.ConsilxDeep 6 AIKoneksa Health Inc.Medidata SolutionsOraclePatientsLikeMeTrialbeeTriNetX, Inc.Veeva Systems.Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart)https://www.databridgemarketresearch.com/toc/?dbmr=global-pharma-clinical-trial-digitization-market&ab

This Pharma Clinical Trial Digitization Market Research document takes into consideration several industry verticals such as company profile, contact details of manufacturer, product specifications, geographical scope, production value, market structures, recent developments, revenue analysis, market shares and possible sales volume of the company. It consists of most-detailed market segmentation, systematic analysis of major market players, trends in consumer and supply chain dynamics, and insights about new geographical markets. The market insights and analysis provided in this market research document are based upon SWOT analysis on which businesses can trust confidently. This Pharma Clinical Trial Digitization report is produced by chewing over several fragments of the present and upcoming market scenario.

Global Pharma Clinical Trial Digitization Market Segments & Geographic Analysis:

By Services (Drug Dose Adjustment, Drug Impact Monitoring, Medical Prescription System, Bioprinting, Preventive Therapy, Individualized Drug Printing)

By Application (Clinical Data Management, Trial Monitoring, Patient Recruitment and Enrollment)

By Themes (Digital Continuity Across Clinical Trial IT Systems, Patient-centric Remote and Virtual Trial Design, Direct-to-patient Home Services)

Pharma Clinical Trial Digitization Market-Geographical Segment

North America (Canada, United States & Mexico)Europe (Germany, the United Kingdom, BeNeLux, France, Russia & Italy)Asia-Pacific (Japan, South Korea, China, India & Southeast Asia)South America (Argentina, Brazil, Peru, Colombia, Etc.)Middle East & Africa (United Arab Emirates, Egypt, Saudi Arabia, Nigeria & South Africa)Global Pharma Clinical Trial Digitization Market Scope and Market Size

Pharma clinical trial digitization market is segmented of the basis of services, application and themes. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

On the basis of services, the pharma clinical trial digitization market is segmented into drug dose adjustment, drug impact monitoring, medical prescription system, bioprinting, preventive therapy, and individualized drug printing.

Based on application, the market is segmented into clinical data management, trial monitoring, patient recruitment and enrollment.

The pharma clinical trial digitization market on the basis of theme is segmented into digital continuity across clinical trial it systems, patient-centric remote and virtual trial design and direct-to-patient home services.

Years considered for this report:o Historical Years: 2010-2019o Base Year: 2019o Estimated Year: 2020o Pharma Clinical Trial Digitization Market Forecast Period: 2020-2027

With tables and figures helping analyses worldwide Global Pharma Clinical Trial Digitization market trends, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Table of Content:

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the global Pharma Clinical Trial Digitization Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition byCompany:Here, the competition in the Worldwide Pharma Clinical Trial Digitization Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Pharma Clinical Trial Digitization Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Pharma Clinical Trial Digitization Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Pharma Clinical Trial Digitization Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Pharma Clinical Trial Digitization Market.

Market Forecast:Here, the report offers a complete forecast of the global Pharma Clinical Trial Digitization Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

Customization Service of the Report:

Data Bridge Market Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team (Corporatesales@databridgemarketresearch.com), who will guarantee you to get a report that suits your necessities.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:Corporatesales@databridgemarketresearch.com

Read the rest here:
Pharma Clinical Trial Digitization Market Size, Share, Revenue, Demand and Forecasted Healthcare Industry with Upcoming Trends and Expectations by...

Our virtualMedCity INVEST Precision Medicine conference, December 9-11, will highlight aspects of precision medicine from the biopharma companies developing cell and gene therapies to diagnostics and the data sharing initiatives to support precision and personalized medicine.

One vexing part of any conversation on precision medicine and breakthrough therapies that have been developed and are continuing to work their way through clinical trials for cancer to rare disease is how to address the practical challenge of their high price tags. Although there are several models to cover the cost of these therapies such as Cignas Embarc Benefit Protection program,what happens when someone changes insurers when they change their job? What is fair for patients and whats fair for companies? When do these conversations even start?

The panel, Reimbursement Models for Cell and Gene Therapies, will highlight some of the pros and cons of different models that are coming to market. Panelists include Laura Okpala, Director, Reimbursement Policy, Gilead Sciences, and Mark Trusheim, Strategic Director, NEWDIGS initiative at the MIT Center for Biomedical Innovation.

Heres a preview of some of the sessions. Click here to see the agenda.

Interoperability Progress Report

How far have we progressed with sharing patient medical records? Patient data is key in unlocking riddles of medical science but interoperability is necessary to facilitate this. What companies are making an impact on a regional and national scale? What milestones are on the horizon? What obstacles continue to vex further advancement? How can we make medical records more accessible to patients?

Moderator: Elise Reuter, Senior Reporter, MedCity NewsSpeakers:Kevin Chaney, Senior Program Manager, Office of the National Coordinator for Health ITIda Sim, M.D., Ph.D., Professor of Medicine, University of California, San FranciscoNiko Skievaski, Co-Founder and President, Redox

What It Takes To Build A Successful, Regional BioInnovation HubPhiladelphia is one of many cities seeking to support the continued growth of cell and gene therapy and connected health industries. What do cities need to do to address education, training and other needs to support these sectors? This session will be held as part ofVenture Cafe Philadelphia.

(sponsored by IBX)

Lisa Dalton, Chief People Officer,Spark TherapeuticsAudrey Greenberg, Executive Managing Director,The Discovery LabsTiffany Wilson, President & CEO,University City Science Center

Moderator:Michelle Histand, Director of Innovation, Independence Blue Cross

Register nowand be part of the conversation at INVEST Precision Medicine.

More here:
Navigating the challenge of covering breakthrough therapies at MedCity INVEST Precision Medicine - MedCity News

This article is part of an op-ed series on engineering fields that will change the world byRutgers School of Engineeringfaculty.

By Umer Hassan

Real-world innovations from submarines to self-driving cars come straight from imaginary worlds of science fiction. Think Star Treks handheld tricorder, a medical diagnostic device that made its first appearance in the original TV series. This sci-fi precursor is now changing the face of personalized medicine by taking the tricorder concept to the next level.

Today, diabetics can anticipate a biosensor able to monitor their glucose levels through perspiration. A biosensor implant could detect genetic mutations as they happen, while British researchers are developing a wearable biosensor that will collect data and assess the efficacy of rehabilitation equipment and exercise.

Other biosensors will be able to quickly and inexpensively detect costly and potentially fatal medical conditions such as sepsis and AIDS. Together with Rutgers University colleagues, clinical and industry partners, my lab has been working to solve these global health challenges with new tools that focus on a highly personalized approach to medicine. Since the COVID-19 pandemic began, we are also hoping to apply this technology to fight the coronavirus.

Sepsis the bodys life-threatening response to infection is not only deadly, it is the most expensive inpatient medical condition in the United States, with patients who develop sepsis often spending days in intensive care units at a cost of $10,000 a day or more. Recognizing that sepsis is responsible for as many as 6 million largely preventable deaths a year, the World Health Organization has identified the prevention, diagnosis and management of sepsis as a pressing global health priority.

By applying electrical and computer engineering skills to identify new biomarkers and devise machine-learning algorithms, or artificial intelligence systems, we hope to dramatically improve clinicians' abilities to diagnose, predict and ultimately manage sepsis. Simply reacting to diseases is no longer enough we need to predict them in order to treat patients in a much smarter way.

To this end, we are building an inexpensive medical device that even minimally trained health care providers can use to accurately diagnosis sepsis. This automated device would cost less than $10 a test and be simple to operate not only in resource-limited settings but anywhere where a rapidly confirmed diagnosis of sepsis is needed.

In sub-Saharan Africa, where only one person in eight is even tested for HIV, many of those infected go undetected until they develop severe complications from the disease. In the near future, cheap, disposable biosensors that are as easy and convenient to use as a home pregnancy test, will detect infections with people living with HIV/AIDS in underdeveloped sub-Saharan African nations. A secondary goal is to develop sensors able to monitor a patients response to the antiretroviral therapy they receive.

The positive health and economic impact of such sensors would be felt not only in underdeveloped nations, but also in the United States by reducing the cost of a single HIV test from hundreds of dollars to as little as $10.

A smartphone-based microscope setup, working with a Galaxy S9+ attached to a 3D printed platform will display an image of white blood cells.

My lab has also made the fight against COVID-19 a priority and a natural extension of our existing work. We are seeking to develop a sensor that could measure the ability of white blood cells to kill the virus in high-risk human patients. This could lead to new therapeutic interventions and could help develop a rapid, easy-to-use widespread stratification test.

In terms of predicting health outcomes and personalizing therapeutic approaches economically, we are also collaborating with Robert Wood Johnson Medical Hospital to do just that by combining sensor data and electronic medical records data.

Advancing personalized medicine and health monitoring is also a key concern of my Rutgers School of Engineering colleague, electrical and computer engineering associate professor Mehdi Javanmard. His lab has been developing a lab on a chip with the potential to monitor everything from health to germs to pollutants.

His teams innovative biosensor could be used in hand-held devices akin to that old Star Trek tricorder or wearable devices that measure biomarkers to track your health and exposure to harmful bacteria, viruses, and pollutants.

While a single biomarker is measured in home pregnancy tests, multiple biomarkers need to be tracked simultaneously to diagnose and manage complex health conditions such as heart disease, cancer, and inflammatory diseases. The lab on a chip is designed to meet that challenge. Additionally, within the next three to five years, a lab on a chip could quickly analyze a sample of what if any harmful bacteria are on a doorknob of a bathroom; test a salad for the presence of E. coli or Salmonella bacteria; or even quickly test for the flu.

In time, a future version of the smartphone will be the true tricorder of tomorrow. Smartphone-based health sensors will ultimately transform the smartphone into an intelligent, all-in-one monitoring and diagnostic device.

Umer Hassan, an assistant professor of electrical and computer engineering at Rutgers University School of Engineering, holds a joint appointment at Rutgers Global Health Institute.

Our journalism needs your support. Please subscribe today to NJ.com.

Heres how to submit an op-ed or Letter to the Editor. Bookmark NJ.com/Opinion. Follow us on Twitter @NJ_Opinion and on Facebook at NJ.com Opinion. Get the latest news updates right in your inbox. Subscribe to NJ.coms newsletters.

See original here:
Star Trek-inspired personalized medicine is on the horizon | Opinion - NJ.com

Ibex Medical Analytics, a company in artificial intelligence (AI)-based cancer diagnostics and Institut Curie, Frances leading cancer center, today announced a research partnership aimed at improving diagnosis of breast cancer with AI.

Breast cancer is the most common malignant disease in women worldwide, with over 2 million new cases each year. As such, accurate and timely diagnosis of breast cancer is instrumental in guiding treatment decisions and improving patient survival rates. Analysis of breast tissue samples by a pathologist, typically using gross exam followed by examination under a microscope of tissue sections from biopsies or surgical specimens, remains the standard method of diagnosing and staging cancer. However, in recent years, an increase in cancer prevalence, coupled with a decline in the number of pathologists specialized in diagnosing cancer, has resulted in greater workloads and relatively long wait times for test results. Clearly, there is a growing need for automated solutions and decision support tools that can help pathologists diagnose cancer to the utmost accuracy more rapidly, while enabling comprehensive and affordable quality control.

This research partnership, the first of its kind, will include a rich dataset of breast biopsy slides, digitized using a digital pathology scanner, and analyzed for cancer detection by Ibexs Galen Breast solution. Independently, multiple pathologists from Institut Curie will diagnose the slides, followed by blinded analysis of the AI-solutions performance. Galen Breast, the first AI solution used for detection of breast cancer in pathology, was developed utilizing state-of-the-art AI and machine learning techniques, and trained on hundreds of thousands of image samples. The solution is already deployed at the pathology institute of Maccabi Healthcare Services, Israels second largest HMO, where it is used as a second read application.

The importance of breast pathology is ever increasing, as new and more personalized treatments for breast cancer become available, many of which are based on precision medicine and require more tests and diagnosis by pathologists, said Dr. Anne Vincent-Salomon, Director of Pathology at Institut Curie and the principal investigator in the study. We believe that artificial intelligence can help us meet these challenges, and we are delighted to partner with Ibex, the leader in AI for cancer diagnosis in pathology. This collaboration will enable our pathologists to experience AI firsthand and evaluate its utility for diagnosing breast cancer.

We are excited to partner with Institut Curie, a global leader in research and treatment of breast cancer, for the first-ever blinded and independent evaluation of an AI-solution for breast cancer detection, said Daphna Laifenfeld, PhD, Chief Scientific Officer at Ibex Medical Analytics. Our Galen Prostate solution has demonstrated outstanding clinical outcomes and empowers pathologists worldwide to improve diagnostic accuracy and implement 100% quality control. We are continuing to expand our platform to new tissue types, focusing this time on breast biopsies, and are thrilled to work with Dr. Vincent-Salomon and her world-leading team on this important breast cancer study.

"This collaboration illustrates Institut Curie's approach to partnership-based research, combining the expertise of clinicians with the know-how of an innovation-driven technology company, added Amaury Martin, PhD, Head of Technology Transfer and Industrial Partnerships Office at Institut Curie and Head of Carnot Curie Cancer. It illustrates our commitment to play a major role in the development of artificial intelligence approaches applied to personalized medicine.

More:
Ibex Medical Analytics and Institut Curie Partner to Improve AI-Powered Breast Cancer Detection - Technology Networks

Metabolites, the small non-polymeric molecules, which are the intermediate or final products of metabolic reactions, have emerged as powerful tools for biomedical research and precision medicine.The term metabolome, introduced in 1998, represents the whole entity of metabolites within a cell, tissue or entire organism.1Since then, metabolomics has gained impressive traction, especially due to its relevance in systems biology or the holistic approach of deciphering the complexity of biological processes. Metabolomics fits perfectly in that concept, with its strategic position downstream of genomics and transcriptomics in the omics cascade and also tightly connected and influenced by the surrounding environmental factors. Often, the metabolome provides insights where genomic profiling fails to explain a given phenotype, and for this, the field is gaining appreciation from a plethora of pathology-related areas, including cancer, diabetes and cardiac disease.2From a technical point of view, metabolite profiling relies on the principles of analytical chemistry. The main methods are mass spectrometry (ms), applied in a targeted or untargeted manner, nuclear magnetic resonance (NMR) and stable isotope labeling for matabolomic flux analysis. Each of these methods has its pros and cons and the choice depends on the study's final goals. 3, 4The diverse nature of the metabolome continually challenges researchers and creates a colorful array of opinions on which is the most comprehensive and precise approach.

"That's kind of the way targeted metabolomics is. You're looking for certain molecules, but you're only looking under the lights. And if it turns out that this is where you've lost your keys, then it works extremely well." Patti says. Nevertheless, the scientist highly appreciates the significance of targeted metabolomics: "Targeted metabolomics is extremely useful in the clinical arena and other areas of biology," but also acknowledges the importance of identifying novel metabolites and making new discoveries. "The advantage of untargeted metabolomics is the potential for discovering molecules or metabolites that are altered in a particular disease state or physiological condition that are not expected."

Patti's lab leverages on identifying new metabolites using untargeted metabolomics and he is no stranger to the obstacles this approach offers and how it differs from the targeted analysis. "When you do untargeted metabolomics, you don't know what you're looking for. The metabolic spaces are pretty ambiguous, and we can't optimize methods in the classical way that you would do in a targeted experiment," he reflects.

Newgard has a clear vision for the future and the potential of his method: "Where I see us going is always to have that strong foundation of targeted and quantitatively reproducible and rigorous profiling, but then link it to what's happening in metabolic pathways, through the ability to do metabolic flux analysis.

Although somewhat divided into their approaches and tools, metabolomics researchers are unified by their vision for a metabolomics-based approach to personalized medicine in the future, and by the common challenges they encounter and recognize. Their collective efforts will undoubtedly pave the way for deciphering the code of metabolomics.References:

1. Oliver S. Systematic functional analysis of the yeast genome. Trends Biotechnol. 1998;16(9):373-378. doi:10.1016/S0167-7799(98)01214-1.

2. Newgard CB. Metabolomics and Metabolic Diseases: Where Do We Stand? Cell Metab. 2017;25(1):43-56. doi:10.1016/j.cmet.2016.09.018.

3. Zamboni N, Saghatelian A, Patti GJ. Defining the Metabolome: Size, Flux, and Regulation. Mol Cell. 2015;58(4):699-706. doi:10.1016/j.molcel.2015.04.021.

4. McGarrah RW, Crown SB, Zhang G-F, Shah SH, Newgard CB. Cardiovascular Metabolomics. Circ Res. 2018;122(9):1238-1258. doi:10.1161/CIRCRESAHA.117.311002.

5. Kraus WE, Muoio DM, Stevens R, et al. Metabolomic Quantitative Trait Loci (mQTL) Mapping Implicates the Ubiquitin Proteasome System in Cardiovascular Disease Pathogenesis. Lusis AJ, ed. PLOS Genet. 2015;11(11):e1005553. doi:10.1371/journal.pgen.1005553.

6. Yao C-H, Wang L, Stancliffe E, et al. Dose-Response Metabolomics To Understand Biochemical Mechanisms and Off-Target Drug Effects with the TOXcms Software. Anal Chem. 2020;92(2):1856-1864. doi:10.1021/acs.analchem.9b03811.

7.Huang X, Chen Y-J, Cho K, Nikolskiy I, Crawford PA, Patti GJ. X 13 CMS: Global Tracking of Isotopic Labels in Untargeted Metabolomics. Anal Chem. 2014;86(3):1632-1639. doi:10.1021/ac403384n.8. Lu D, Mulder H, Zhao P, et al. 13C NMR isotopomer analysis reveals a connection between pyruvate cycling and glucose-stimulated insulin secretion (GSIS). Proc Natl Acad Sci. 2002;99(5):2708-2713. doi:10.1073/pnas.052005699.

9. Warburg O, Wind F, Negelein E. The Metabolism Of Tumors in the body. J Gen Physiol. 1927;8(6):519-530. doi:10.1085/jgp.8.6.519.

Follow this link:
Diverse Opinions to Common Challenges in the Field of Metabolomics - Technology Networks

Costa Rica has the conditions to move towards the adoption of a personalized health care approach, despite some pending challenges in its objective of impacting the entire population.

A research report Personalized medicine in Latin America: Universalizing the promise of innovation, prepared by the Intelligence Unit of The Economist (EIU, for its acronym in English) indicated this and also highlighted that it is the Central American country with better social, political, economic and health conditions for its application.

To contribute to greater and better local coverage, the study recommends the construction of an initial frame of reference that includes issues of governance, awareness, and attitudes; infrastructure and financial management, where patients, the medical community, and health authorities understand the possibilities and challenges of personalized medicine in aspects such as patient and doctor education, improvements in digital and laboratory infrastructure, transition to advances in medicine, among others issues.

The study had the support of Roche Latin America and in addition to Costa Rica, it included Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Peru, and Uruguay. The nine countries were categorized as level one, two, or three, based on their assessment of the basic elements necessary for the successful implementation of personalized medicine, and where they are in the process.

The report places Costa Rica, Argentina, Brazil, Colombia, and Uruguay at level one, countries that it considers ready to decide, as it has substantial elements of the reference framework, but with important gaps in terms of its evaluation.

The best-prepared

At this level, Costa Rica is the Central American country best prepared to decide whether to create a comprehensive approach encompassing its entire health system and not just separate initiatives, which allows accompanying each patient on their journey, from prevention to treatment, monitoring and identifying their needs.

Follow this link:
Costa Rica is the Only country to advance in Personalized Medicine - The Costa Rica News

LONDON--(BUSINESS WIRE)--The RNA and DNA extraction kit market is poised to grow by USD 731.27 million during 2020-2024, decelerating at a CAGR of almost 9% during the forecast period.

For a More Detailed Analysis, Get a Free Sample Report Delivered in a Minute

The report on the RNA and DNA extraction kit market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.

The report offers an up-to-date analysis regarding the current global market scenario and the overall market environment. The market is driven by the increasing incidence of cancer.

The RNA and DNA extraction kit market analysis includes product and geography landscape. This study identifies the increasing adoption of personalized medicine as one of the prime reasons driving the RNA and DNA extraction kit market growth during the next few years.

This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.

The RNA and DNA extraction kit market covers the following areas:

RNA And DNA Extraction Kit Market Sizing

RNA And DNA Extraction Kit Market Forecast

RNA And DNA Extraction Kit Market Analysis

Develop Smart Strategies for Your Business: Get a Free Sample Report Now!

Companies Mentioned

Related Reports on Health Care Include:

Global DNA Sequencing Market - Global DNA sequencing market is segmented by solution (products and services) and geography (Asia, Europe, North America, and ROW). Click Here to Get an Exclusive Free Sample Report

Global Synthetic Biology Market - Global synthetic biology market is segmented by application (healthcare, industrial, food and agriculture, and others) and geography (Asia, Europe, North America, and ROW). Click Here to Get an Exclusive Free Sample Report

Key Topics Covered:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Product

Customer Landscape

Geographic Landscape

Vendor Landscape

Vendor Analysis

Appendix

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Subscribe to World-Class Market Intelligence and gain instant access to 17,000+ market research reports and connect with expert analysts

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Go here to see the original:
Global RNA and DNA Extraction Kit Market Growth Will Decelerate at a CAGR of Over 9%, 2020-2024 | However, Market Registers an Incremental Growth of $...